best shares


“I felt like a human being who had been dropped into a shark tank.”

Fox News host Megyn Kelly says that’s what it felt like when Donald Trump was attacking her in interviews and in tweetstorms.

Kelly attracted Trump’s ire during the first GOP primary debate in August 2015, when she asked him about his track record of misogynistic comments. Trump criticized her for months afterward, sometimes in highly personal ways, which triggered threats to her safety.


“We had security guards the whole year,” Kelly told Anderson Cooper in an interview on CNN on Wednesday night. “I mean, the threat level just got so high that it was impossible not to take that seriously.”

Kelly wrote about the experience in a new book, “Settle for More,” which came out on Tuesday. She is on a book tour this week, one week after Trump won the presidential election.

In the interview, Kelly recounted how one of Trump’s lawyers, Michael Cohen, retweeted a Twitter user sa ying “we can gut her” at a time of heightened threats.

best shares: Regeneron Pharmaceuticals, Inc.(REGN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    As biotech stocks like Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) get ready to report earnings, Piper Jaffray’s Joshua Schimmer and team write that they “would not be surprised to see the volatility continue.” They explain why:

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    PACCAR Inc (NASDAQ: PCAR) Aug16 52.5 Puts: 10000 @ ASK $1.70: 10k traded vs 335 OI: Earnings 7/26 $54.94 Ref Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Jul16 345 Puts: 949 @ ASK $8.70: 1003 traded vs 55 OI: Earnings 8/2 $360.20 Ref NVIDIA Corporation (NASDAQ: NVDA) Fri 6/24 47.0 Puts (Wkly) Sweep: 689 @ ASK $1.12: 3758 traded vs 136 OI: Earnings 8/4 $46.69 Ref Medivation Inc (NASDAQ: MDVN) Sep16 55.0 Puts: 4000 @ Above Ask! $3.40: 5303 traded vs 716 OI: Earnings 8/4 $59.44 Ref Expeditors International of Washington (NASDAQ: EXPD) Aug16 47.0 Puts Sweep: 950 @ ASK $1.35: 973 traded vs 381 OI: Earnings 8/2 $48.15 Ref


    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

    Agence France-Presse/Getty Images

    Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.

    Chardan’sGbola Amusa takes a victory lap:


    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in i ts favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.


    While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.

    Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) has dropped 1.5% to $407.65 after getting cut to Market Perform from Outperform at Wells Fargo.

    Boeing (BA) has fallen 2.2% to $129.80 after BofA Merrill Lynch cut the airline manufacturer to Underperform from Neutral.

best shares: Gibraltar Industries, Inc.(ROCK)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell by 0.82 percent. Meanwhile, top losers in the sector included Gibraltar Industries Inc (NASDAQ: ROCK), down 9 percent, and Yamana Gold Inc. (USA) (NYSE: AUY), down 9 percent.

  • [By Lisa Levin]

    On Friday, the basic materials sector proved to be a source of strength for the market. Top gainers in the sector included LSB Industries, Inc. (NYSE: LXU), Ferro Corporation (NYSE: FOE), and Gibraltar Industries Inc (NASDAQ: ROCK).

best shares: Portola Pharmaceuticals, Inc.(PTLA)


Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.


    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

best shares: Paychex Inc.(PAYX)

Advisors’ Opinion:

  • [By Monica Gerson]

     

    Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion. ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion. Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion. Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share. Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million. Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million. Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.


    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

  • [By Monica Gerson]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Paychex, Inc. (NASDAQ: PAYX) is estimated to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Paychex shares rose 1.10 percent to close at $56.14 on Wednesday. Wall Street expects Micron Technology, Inc. (NASDAQ: MU) to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. Micron shares rose 0.76 percent to $13.29 in after-hours trading. Pier 1 Imports Inc (NYSE: PIR) reported a wider-than-expected loss for its first quarter and issued a weak outlook. Pier 1 Imports shares dropped 6.07 percent to $5.11 in the after-hours trading session. Analysts are expecting McCormick & Company, Incorporated (NYSE: MKC) to have earned $0.74 per share on revenue of $1.06 billion in the latest quarter. McCormick shares fell 0.59 percent to $102.10 in after-hours trading.

    Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas

  • [By Monica Gerson]

    Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.50 per share on revenue of $751.20 million.

    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.26 per share on revenue of $362.62 million.

Leave a Reply

Your email address will not be published. Required fields are marked *